openPR Logo
Press release

6th Annual Drug Discovery Symposium (SDDS2022)

04-19-2022 09:19 AM CET | Science & Education

Press release from: Stanford Cardiovascular Institute

Stanford Drug Discovery Symposium, April 25-26, 2022, is a free, virtual symposium. It is an exciting opportunity to hear about drug discovery from leaders in the field. Speakers include leaders at major pharmaceutical companies, federal policy makers, venture capitalist investors, IP lawyers, and scientists making groundbreaking advances.

Register for free at tinyurl.com/SDDS2022.

This symposium provides a valuable and important platform for inspiring interdisciplinary exchange at the forefront of drug research and will support a fantastic networking experience. It provides a great resource for researchers, pharmaceutical companies, investment groups, and those in the wider biomedical community interested in discovering new drugs and improving patient care. We look forward to an exciting two days of talks and discussion. Our Lifetime Achievement Award will be given to Katalin Karikó, PhD, Senior VP, BioNTech, whose research was pivotal in creation of the mRNA COVID-19 vaccines.

To download our poster visit: https://med.stanford.edu/content/dam/sm/cvi/documents/pdf/2022/sdds-2022-poster-v2.pdf.

265 Campus Drive, G1120, Stanford, CA 94305
Press: 650-725-7964
preston@stanford.edu

https://tinyurl.com/SDDS2022

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 6th Annual Drug Discovery Symposium (SDDS2022) here

News-ID: 2602631 • Views: 577

More Releases from Stanford Cardiovascular Institute

5th Stanford Drug Discovery Symposium (SDDS 2021) held virtually this year! Apri …
STANFORD, CA, USA, March 22, 2021 -- Featuring talks from drug discovery leaders the Stanford Drug Discovery Symposium, April 19-20, 2021, is a free, virtual symposium hosted by Stanford University. This event offers an exciting opportunity for the public to hear about how drug research and development is done in the US and globally. Esteemed guests are from of major pharmaceutical companies, federal policy makers, venture capitalists, start-up companies, and

More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug